AI assistant
Quoin Pharmaceuticals, Ltd. — Director's Dealing 2023
Jan 3, 2023
35443_dirs_2023-01-03_4451f512-f086-4684-a454-b1fea9fe5e84.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2023-01-01
Reporting Person: Myers Michael (Director, Chief Executive Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 561480000 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Share Option (right to buy) | $0.0035 | 2032-04-12 | Ordinary Shares (428571600) | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents five thousand (5,000) ordinary shares of the Issuer.
F2: The option vests in four equal annual installments beginning on April 12, 2023.
F3: The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer
represented by one (1) ADS, which evidences the grant of an option to buy 85,714.32 ADSs at the exercise price of $17.50 per ADS.